Publications by authors named "Kevin Sermet"

Article Synopsis
  • The study aimed to evaluate whether the QuantiFERON®-CMV test could predict CMV recurrence in heart transplant recipients and improve the management of secondary prophylaxis duration.
  • Out of 15 patients with CMV infection, 33% experienced recurrence, but the QuantiFERON®-CMV test did not significantly correlate with recurrence rates or the length of prophylaxis.
  • The findings suggest that the QuantiFERON®-CMV assay may not be effective for predicting CMV recurrence in this patient group, indicating a need for alternative tests and treatment strategies, such as using everolimus in immunosuppressive regimens.
View Article and Find Full Text PDF

Gastro-intestinal mucormycosis (GIMM) is a highly lethal invasive fungal disease partly because of a challenging diagnosis. An allogeneic hematopoietic cell transplant recipient experienced bowel obstruction caused by slowly-evolutive gastro-intestinal mucormycosis and was successfully treated with surgery and antifungal therapy. Pathological findings revealed a granuloma without angio-invasion, which is unusual in this fungal disease and has incomplete similarities with an immune reconstitution inflammatory syndrome.

View Article and Find Full Text PDF

A non-typeable (NTHi) was responsible for an invasive infection including bacteremia, spondylodiscitis with epidural abscess, and periprosthetic hip infection in a 79-year-old woman, triggered by a superinfected ethmo-orbital mucocele. Surgical drainage and antibiotic therapy allowed recovery. PET-scan full cartography of NTHi infection dissemination enabled the discovery of spondylodiscitis.

View Article and Find Full Text PDF

A 65-year-old man was diagnosed with an invasive Aspergillus fumigatus infection with sternal osteomyelitis 4 months after heart transplantation. Unfortunately, after 8 weeks patient developed severe cutaneous and neurological toxicities induced by voriconazole leading to drug discontinuation. Therefore, isavuconazole was chosen as second-line therapy.

View Article and Find Full Text PDF